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Abstract
Objective To identify existing prediction models for the risk of
development of type 2 diabetes and to externally validate them in a large
independent cohort.
Data sources Systematic search of English, German, and Dutch
literature in PubMed until February 2011 to identify prediction models
for diabetes.
Design Performance of the models was assessed in terms of
discrimination (C statistic) and calibration (calibration plots and
Hosmer-Lemeshow test).The validation study was a prospective cohort
study, with a case cohort study in a random subcohort.
Setting Models were applied to the Dutch cohort of the European
Prospective Investigation into Cancer and Nutrition cohort study
(EPIC-NL).
Participants 38 379 people aged 20-70 with no diabetes at baseline,
2506 of whom made up the random subcohort.
Outcome measure Incident type 2 diabetes.
Results The review identified 16 studies containing 25 prediction models.
We considered 12 models as basic because they were based on
variables that can be assessed non-invasively and 13 models as
extended because they additionally included conventional biomarkers
such as glucose concentration. During a median follow-up of 10.2 years
there were 924 cases in the full EPIC-NL cohort and 79 in the random
subcohort. The C statistic for the basic models ranged from 0.74 (95%
confidence interval 0.73 to 0.75) to 0.84 (0.82 to 0.85) for risk at 7.5
years. For prediction models including biomarkers the C statistic ranged
from 0.81 (0.80 to 0.83) to 0.93 (0.92 to 0.94). Most prediction models
overestimated the observed risk of diabetes, particularly at higher
observed risks. After adjustment for differences in incidence of diabetes,
calibration improved considerably.
Conclusions Most basic prediction models can identify people at high
risk of developing diabetes in a time frame of five to 10 years. Models
including biomarkers classified cases slightly better than basic ones.
Most models overestimated the actual risk of diabetes. Existing prediction
models therefore perform well to identify those at high risk, but cannot
sufficiently quantify actual risk of future diabetes.
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Type 2 diabetes is a large burden in healthcare worldwide.1
Studies on lifestyle modifications and drug intervention have
convincingly shown that these measures can prevent diabetes.2 3
Early identification of populations at high risk for diabetes is
therefore important for targeted prevention strategies and is
necessary to enable proper efforts to be taken for prevention in
the large number of individuals at high risk, while avoiding the
burden of prevention and treatment for the even larger number
of individuals at low risk, both for the individual and for society.
The professional practice committee of the American Diabetes
Association recommends screening for all overweight or obese
adults (body mass index (BMI) ≥25) of any age who have one
or more additional risk factors for diabetes such as family history
or hypertension.4 The European evidence based guidelines for
the prevention of type 2 diabetes5 and the International Diabetes
Federation6 recommend the use of a reliable, simple, and
practical risk scoring system or questionnaire to identify people
at high risk of future diabetes.
During the past two decades, many such prediction models have
been developed.7-11 Three recent reviews on this topic described
existing prediction models and the predictive value of specific
risk factors (such as metabolic syndrome) over a wide range of
populations.7-9 Surprisingly, however, the performance of less
than a quarter of the prediction models was externally
validated.9-11 Because the performance of a prediction model is
generally overestimated in the population in which it was
developed, external validation of suchmodels in an independent
population, ideally by researchers not involved in the
development of the models, is essential to broadly evaluate the
performance and thus the potential utility of such models in
different populations and settings.12-15 Consequently, certain
prediction models to identify those at high risk of diabetes
cannot be recommended when external validity of available
models is unknown.12 16 Moreover, a direct comparison of the
performance of the existing models in the same (external)
validation cohort is essential to bridge the gap between the
development of models and the conduct of studies for clinical
utility.
The recent systematic reviews highlighted the need for an
independent study to identify the existing prediction models
and subsequently validate and compare their performance to
support the current recommendations.7-9 Few studies have
externally validated suchmodels, commonly not more than two
or three at once, and almost always in medium sized
cohorts.10 11 14 17 We applied a more comprehensive approach as
recently suggested.14 15 Firstly, we carried out a systematic
review to identify the most relevant existing models for
predicting the future risk of type 2 diabetes. Then we used
various analytical measures for validating18 and comparing their
predictive performance in a large independent general population
based cohort—the Dutch cohort of the European Prospective
Investigation into Cancer and Nutrition (EPIC-NL).19
Methods
Systematic literature search
We performed a systematic literature search according to the
PRISMA guidelines,20 when applicable. We searched PubMed
for all published cohort studies that reported prediction models
for the risk of type 2 diabetes until February 2011 using the
following search string: ((“diabetes” OR “diabetes mellitus”
OR “type 2 diabetes”) AND (“risk score” OR “prediction
model” OR “predictive model” OR “predicting” OR “prediction
rule” OR “risk assessment” OR “algorithm”)) NOT review [pt]
AND English [LA]. We repeated this search for publications in
German and Dutch. Finally, we checked systematic reviews and
validation studies of prediction models to identify other relevant
articles for our validation study. Because we did not perform a
formal meta-analysis, the PRISMA items related to “protocol
and registration” and “synthesis of results” for meta-analyses
are not applicable to our study.
Studies were included if they met the following criteria: the
study presented at least one formal predictionmodel or an update
on a previously developed model; the endpoint was incident
type 2 diabetes in a longitudinal design; and the population had
to be at least partly white because the EPIC-NL cohort to be
used for validation consists predominantly of white adults. We
excluded studies using data on individuals with impaired glucose
tolerance or impaired fasting glucose. Furthermore, we excluded
models that used the two hour oral glucose tolerance test as a
predictor variable because this was not available in our
validation dataset and there was no reliable proxy variable
available that could be taken as a substitute.
After review of the retrieved titles, two authors (AA and JWJB)
independently reviewed the abstracts to select the relevant papers
for full text review and subsequently reviewed and assessed the
full papers. Discrepancies between the two reviewers were
solved by having a third author (EC) review to reach consensus.
For included studies, we made a primary plan to extract
necessary data from the original studies to validate the models
or contact the authors to obtain this information.
Table 1 summarises characteristics of the included studies⇓.
The extracted data included the first author’s name, year of
publication, country, name of study/score, number of cases and
population, ascertainment of diabetes, duration of follow-up,
statistical model, number of predictors, and reported
performance of the model. The retrieved models were divided
into models that contained only non-invasive predictors (“basic
models”) and models that also included conventional
biomarkers, such as glucose, HbA1c lipids, uric acid, or
γ-glutamyltransferase (“extended models”).
Validation cohort
The EPIC-NL cohort (n=40 011) includes theMonitoring Project
on Risk Factors for Chronic Diseases (MORGEN-EPIC) and
Prospect-EPIC cohorts, initiated between 1993 and 1997. The
Prospect-EPIC cohort comprises 17 357 women aged 49-70
who participated in a breast cancer screening programme. The
MORGEN cohort comprises 22 654men andwomen aged 20-64
who were recruited through random population sampling in
three Dutch towns (Amsterdam, Maastricht, and Doetinchem).
At baseline, all participants were sent a general questionnaire
and a food frequency questionnaire; these were returned when
they visited the study centre for a medical examination.
Reporting of the study results conforms to STROBE along with
references to STROBE.21
We excluded 615 individuals with prevalent type 2 diabetes and
1017 with missing follow-up or who did not consent to linkage
with disease registries. The 38 379 remaining participants were
used to validate the basic models in a full cohort design. We
applied similar exclusion criteria in a 6.5% baseline random
sample (n=2604) in which measurements of conventional
biomarkers were available,19, leaving 2506 individuals.We used
this random sample and all incident cases of type 2 diabetes to
validate the extended models in a case cohort design.22 Table A
in appendix 1 provides baseline characteristics for the entire
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cohort, the random sample, and the people with incident type
2 diabetes.
Assessment of predictor variables
Variables in the prediction models included in this study were
assessed with a baseline general questionnaire for disease history
and lifestyle variables. A validated food frequency questionnaire
filled in at baseline was used to assess nutritional variables.23
During the baseline visit, body weight, height, waist, and hip
circumference, and blood pressure were measured and blood
samples were drawn. Details of these procedures have been
described elsewhere19 and are shown in appendix 2.
Assessment of type 2 diabetes
Occurrence of diabetes during follow-up was self reported via
two follow-up questionnaires at three to five year intervals in
the MORGEN and Prospect cohort. In the Prospect cohort,
incident cases of diabetes were also detected as glucosuria via
a urinary glucose strip test, which was sent out with the first
follow-up questionnaire. Diagnoses of diabetes were also
obtained from the Dutch Center for Health Care Information,
which holds a standardised computerised register of diagnoses
at hospital discharge. Follow-up was complete up to 1 January
2006. Potential cases identified by these methods were verified
against general practitioner (MORGEN and Prospect) or
pharmacist records (Prospect only). Diabetes was defined as
present when the diagnosis was confirmed by either of these
methods. For 89% (n=1142) of participants with potential
diabetes, verification information was available, and 72%
(n=924) were verified as having type 2 diabetes and were
included as cases of type 2 diabetes in this analysis.24
Data analysis
To evaluate the predictive performance of the retrieved
prediction models, we used the original prediction models
(regression coefficients with intercept or baseline hazard) as
published. If the paper did not contain sufficient information,
we asked the authors to provide us with the original model.25 26
Particularly, we obtained regression coefficients26 and the
intercept of the model25 by asking for complementary
information. Using these original (regression) model formulas,
we calculated the probability of developing type 2 diabetes per
model for each individual in our study sample. Two authors
(AA and JWJB) first matched the predictors of the original
models with the variables available in our data. A direct match
was available in our data for most variables. If a direct match
was not possible, we replaced the original predictor with a proxy
variable to avoid having to drop the model from our validation
study. For example, we used non-fasting glucose values because
fasting glucose values were not available in our data. Also,
nutritional variables were collected with our food frequency
questionnaire as continuous variables (g/day) and were re-coded
into corresponding categories used in the prediction models by
using Dutch portion sizes. Table B in appendix 1 provides an
overview of the variables used in each of the prediction models,
and appendix 2 gives the exact details on the proxy variables
that were used.
We assessed performance of the models using measures of
discrimination and calibration.13 Discrimination describes the
ability of the model to distinguish those at high risk of
developing diabetes from those at low risk. The discrimination
was examined by calculating Harrell’s C (comparable with the
area under the ROC curve), accounting for censored data.27
Calibration indicates the ability of the model to correctly
estimate the absolute risks and was examined by calibration
plots. In a calibration plot, the predicted risk is plotted against
the observed incidence of the outcome. Ideally the predicted
risk equals the observed incidence throughout the entire risk
spectrum and the calibration plot follows the 45° line. The
calibration plot was extended to a “validation” plot as a summary
tool.18 27Appendix 2 gives more details on information provided
by this plot. Calibration was also tested with the
Hosmer-Lemeshow goodness of fit statistic for time to event
data.18 27 Follow-up of our cohort was almost complete until
about eight years: 3%were censored at 5 years, 5% at 7.5 years,
and 44.6% at 10 years. To account for censoring when obtaining
the observed probabilities for assessing calibration over, say,
10 years of follow-up, we first calculated for each individual
the linear predictor and subsequently 10 year predicted outcome
probability by the original survival models. This predicted
probability was then divided into tenths, and we performed a
Kaplan-Meier analysis per tenth, which accounts for the
observed censoring. Per tenth, we obtained at the 10 year time
point the observed outcome percentages, which in turn were
compared with the 10 mean predicted outcome probabilities to
obtain the calibration plot and measure of goodness of fit. This
was done for each model and for the other time points (5 and
7.5 years).28Moreover, we reported the calibration slope for the
logistic regression models18 and calculated observed over
predicted (expected) outcomes (O/E ratio) with 95% confidence
intervals.18 29 A ratio below 1.0 indicates overestimation of risk,
and a ratio more than 1.0 indicates underestimation of risk.
Differences in the incidence of diabetes in our cohort and in the
development populations led to significant deviation between
observed risk in our cohort and predicted risk estimated by the
prediction model. To reduce this source of miscalibration, we
“recalibrated” each prediction model by adjusting the intercept
(for logistic regression models) or the baseline survival function
(for survival regression models).28 30 31
The original models were developed for different time periods
of risk prediction (different “prediction horizons”)—for instance,
some models estimate 5 year risk and others 10 year risk. We
therefore assessed the performance of each model for prediction
of risk at 5, 7.5, and 10 years to account for the different time
periods. For example, for 5 year risk, we considered individuals
as incident cases if they had developed diabetes within the first
five years of follow-up. Participants who developed diabetes
after more than five years of follow-up were included in five
year prediction as non-cases. A similar approach was followed
for 7.5 and 10 year predictions. In addition, we performed a
sensitivity analysis using the prediction horizon for which each
model was developed in case this differed from 5, 7.5, or 10
years.
For the basic prediction models, which included only data from
non-invasive clinical variables, we quantified their performance
in the full dataset. The extended models were validated in the
case cohort data. To account for this design, we applied an
extrapolation approach that extends the case cohort data to the
size of the full cohort.22 This is achieved by extrapolating the
non-cases of the random sample (that is, the total random sample
of 2506 individuals minus 79 cases) to the number of non-cases
in the full cohort (that is, the total sample of 38 379 individuals
minus 924 cases). To do so, we substituted the non-cases in the
full cohort (n=37 455) with a randommultiplication of non-cases
of the random sample (n=2427). On average, we multiplied the
non-cases in the random sample by 15.4 (that is, 37 455 divided
by 2427). Next, wemerged the extrapolated data from non-cases
to those from all the cases (total non-cases of 37 455 individuals
plus 924 cases), recreating the size and composition of the full
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cohort. In sensitivity analyses, we estimated the performance
of the basic models in the re-sampled data from the case cohort
and compared these results with those obtained from the full
cohort. This allowed us to confidently use the extrapolation
approach for the extended models in the case cohort design.
For most predictors data from less than 1% of the values were
missing, although missing values occurred in 5% for family
history of diabetes, about 15% for physical activity, and 20.5%
for non-fasting glucose concentrations. Because an analysis of
only the completely observed participants could lead to biased
results,32-34 we imputed these missing values using single
imputation and predictive mean matching. As the percentage
of missing values for the non-fasting glucose concentration was
high, we repeated our analyses using only data from the
MORGEN cohort, in which less than 10% of values for
non-fasting glucose concentration were missing, as a sensitivity
analysis. Table C in appendix 1 shows the number of missing
values for all variables incorporated in the original model.
We carried out a third sensitivity analysis to account for the use
of non-fasting glucose values, as we had to approximate the
fasting glucose values included in the models by the non-fasting
glucose values in our data. In this analysis, we excluded
individuals with a non-fasting glucose of ≥11.1 mmol/L
(n=130), as this cut point is considered as a high blood glucose
concentration at which diabetes is suspected especially if it is
accompanied by the classic symptoms of hyperglycaemia.4 In
another sensitivity analysis, we excluded 19 295 individuals
(including 537 incident cases of diabetes) with fasting period
of under two hours. In a fifth sensitivity analysis we excluded
255 individuals for whom we had no verification information
of diabetes status.
All statistical analyses were conducted with SPSS version 18




We scanned 7756 titles and selected 134 abstracts for review.
Figure 1⇓ depicts the flow of the study selection process. We
selected 46 articles for full text review and added six that were
identified from other sources such as recent systematic
reviews.7-9 After full review of these 52 articles, we excluded
36 as they did not meet all inclusion criteria (appendix 3). The
main reasons for exclusion were no prediction of the future risk
of diabetes (n=15); validation study (n=10); no formal prediction
models provided (n=6); and incomparable derivation populations
(n=2) or unavailable data of predictors (n=3). Of three studies
that used data from two hour oral glucose tolerance tests, we
excluded two because they were cross sectional and one because
it did not provide any prediction model.
Table 1 summarises the characteristics of the 16 studies included
in this validation study.25 26 35-48 Eleven studies described 34 basic
models based on data that can be assessed non-invasively,
including demographics, family history of diabetes, measures
of obesity, diet, and lifestyle factors, blood pressure, and use of
antihypertensive drugs. Of these 34 basic models, 12 models
were presented as the final model.8
Nine studies described 42 extended models including data on
one to three conventional biomarkers such as glucose, HbA1c,
lipids, uric acid, or γ-glutamyltransferase. Of these 42 extended
models, 13 models were presented as the final model. The C
statistics in the development datasets ranged from 0.71 for the
Atherosclerosis Risk in Communities (ARIC)model to 0.86 for
the FINDRISC full model. Only half of the studies reported
measures of calibration, and almost all showed good calibration
in the development datasets. Table B in appendix 1 shows the
variables that are part of the prediction models.
Validation of prediction models
Table A in appendix 1 summarises the baseline characteristics
of participants in the EPIC-NL study (for the full cohort, random
sample, and incident cases of type 2 diabetes). During a median
follow-up of 10.2 years (over 387 000 person years), we
observed 924 incident cases (rate of 2.2 per 1000 person years).
The observed 5, 7.5, and 10 year risks of incident diabetes were
1.3%, 1.8%, and 2.3%, respectively.
Tables 2⇓ and 3⇓ show the performance of the basic models
and the extended models, respectively. The basic models
performed well in terms of discrimination, with C statistics
ranging from 0.74 (95% confidence interval 0.73 to 0.75) to
0.84 (0.82 to 0.85) for the prediction of risk of diabetes at 7.5
years. Similar but slightly higher C statistics were found for the
5 year risk prediction and slightly lower for the 10 year risk
prediction of incident diabetes.
For the extended models, the discrimination was higher, with
C statistics ranging from 0.81 (0.80 to 0.83) to 0.93 (0.92 to
0.94) for the risk at 7.5 years. Similar, but again slightly higher,
C statistics were found for the 5 year risk prediction and slightly
lower for the 10 year risk prediction of incident diabetes.
Both basic and extended models showed a poor calibration
based on the Hosmer-Lemeshow test (P<0.001). Except for the
EPIC-Norfolk and PROCAMmodels, all models overestimated
the predicted against the observed 7.5 year risk of diabetes by
38.9% to more than 100%. Similarly, all observed to expected
ratios were different from 1.0 (tables 2 and 3⇓⇓). The
EPIC-Norfolkmodel underestimated the 7.5 year risk of incident
diabetes by 73.9%. Figure A in appendix 4 shows the calibration
plots for the original models.
After adjustment for differences in the incidence of diabetes
between our cohort and the development populations, all
prediction models showed better calibration (figs 2 and 3⇓⇓).
For some of the models (such as the ARIC basic model) the
calibration plot stayed close to the ideal line throughout the risk
spectrum, whereas others showed severe overestimation,
especially at higher predicted risks (such as Framingham
continuous, DESIR, and BRHS models). Compared with the
original models, the models adjusted for differences in the
incidence of diabetes between the development and validation
cohort performed better, with lower Hosmer-Lemeshow
statistics, but deviation of calibration from ideal was still
significant for all models, except for the KORA basic model
(Hosmer-Lemeshow test P=0.17). For the KORA basic model,
AUSDRISK, and EPIC-Norfolk model, calibration slopes were
close to 1.0, but those were smaller or larger than 1.0 for other
logistic regression models (tables 2 and 3⇓⇓). Figure B in
appendix 5 shows the calibration plots including calibration
statistics for each recalibrated models separately.
To further investigate the different effect size for each predictor,
we compared hazard ratios for predictors between the validation
cohort and one development cohort49 as an example. We used
data from the EPIC-Potsdam study40 because the model was
developed in the German cohort of EPIC using Cox
proportional-hazards regression. Table C in appendix 1 presents
the hazard ratios of the diabetes predictors incorporated in this
risk score compared with those obtained in our validation cohort.
The hazard ratios for age, intake of red meat, physical activity,
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and current heavy smoking differed significantly (P<0.05)
between both cohorts.
Sensitivity analyses
Tables 4⇓ and 5⇓ show the results of sensitivity analyses. Our
results using the extrapolation approach for the case cohort
design were similar when we looked at C statistics and
Hosmer-Lemeshow statistics of 13 basic models obtained from
the extrapolation approach compared with those from the full
cohort design (for example, C statistics ranging from 0.74 (95%
confidence interval 0.72 to 0.76) to 0.84 (0.82 to 0.86), and
Hosmer-Lemeshow test P<0.001). Additionally, our results
using data only from the MORGEN cohort with less than 10%
missing values for non-fasting glucose were comparable with
our results using both cohorts; C statistics ranged from 0.79
(0.76 to 0.81) to 0.92 (0.90 to 0.93) for 13 extended models.
Exclusion of individuals with a non-fasting glucose of ≥11.1
mmol/L did not influence the results, both for the basic (C
statistics ranged from 0.74 (0.72 to 0.75) to 0.83 (0.81 to 0.84))
and the extended models (C statistics ranged from 0.81 (0.80
to 0.83) to 0.93 (0.92 to 0.94)). Moreover, when we excluded
the individuals with less than two hours’ fasting or those without
verified diabetes status, the C statistics were similar to those of
the full cohort analysis. Finally, use of the prediction horizon
for which the original models were developed hardly affected
the results.
Discussion
An evaluation of the performance of 25 prediction models for
type 2 diabetes in an independent Dutch cohort with over 10
years of follow-up showed that basic models perform similarly
well in identifying individuals at high and low risk of developing
diabetes. The performance was slightly better for extended
models that included conventional biomarkers. With regard to
the actual values of the predicted risks, all but two models
overestimated the risk of developing diabetes, which improved
slightly, but not sufficiently, after correction of the models for
differences in incidence of diabetes between development and
validation populations.
Strengths and limitations of study
All models were identified through a systematic literature search,
and we included most existing prediction models in the
validation study. Other strengths included the study’s large
sample size, prospective design, verification of incident diabetes,
and extensive information on individuals’ characteristics.
Nevertheless, some limitations of our study need to be
mentioned. Nearly all participants in the EPIC-NL cohort are
white adults, and further studies are warranted to validate the
models in other populations. In addition, the participation rate
was about 40%.19 50 We previously showed that such a low
response rate might affect prevalence estimates of baseline
characteristics of participants but does not cause bias in the
examined associations.50 We therefore consider that our cohort
is appropriate for the purpose of our study. Although our data
had certain limitations regarding availability of the variables,
wemade an effort to assign all variables and applied definitions
as closely as possible. To handle missing variables, we
performed single imputation and repeated the analysis in one
of the two cohorts with lower missing values for glucose
concentration, which gave similar results. It is therefore unlikely
that these limitations influenced our results to a large extent.
Next, we used data for non-fasting glucose concentration. We
cannot rule out that this affected our results because glucose is
an important predictor of diabetes. We therefore performed
sensitivity analyses in which we excluded individuals with a
non-fasting glucose of ≥11.1 mmol/L4 and those who fasted for
less than two hours, which again yielded similar results. This
is in line with previous studies showing that using non-fasting
lipid concentrations does not influence prediction of, for
example, cardiovascular events.51 52 Because we used data only
from verified potential cases we could have missed false
negative cases in the remainder of the cohort as type 2 diabetes
can remain undiagnosed for several months to years. False
negatives can lead to an underestimation of the C statistic as
the linear predictor resulting from the predictor variables will
be high, whereas their event status is that of a non-case. Given
the large size of our cohort in combination with the low
incidence of diabetes we do not expect this to largely change
our findings. Similarly, false negative cases lead to
underestimation of the observed risk in our cohort and this
influences calibration. We adjusted for this effect, however, by
correcting the intercept of the models to the incidence observed
in our cohort. In addition, as the incidence is expected to be
low,53 potential false negative cases cannot account for the large
overestimations of risk in the models observed in our study.
Moreover, certain development cohorts used similar methods
for verification of diabetes.
External validation of prediction models
The retrieved prediction models differed considerably in terms
of type and number of predictors, age ranges, type of model,
duration of follow-up, and outcome measure. Three recent
systematic reviews presented overviews of studies that
developed these models or validated some selected models.7-9
These reviews, however, also indicated that most of these
models were never validated in an external population. Our
study has now evaluated performance of most developed
prediction models for future diabetes in an external population
and shows that most basic models performwell to identify those
at high risk of diabetes and that extended models perform
slightly better. Generally, the performance of a prediction model
decreases when it is applied in a validation dataset. Despite this,
our study showed that most of the basic models identified those
at high absolute risk well, with C statistic over 0.80. This
discrimination further improved for the extended models with
C statistic of about 0.90. Surprisingly, the C statistics in our
validation study were, in some cases, even higher than in their
original development populations. This might be explained by
differences in heterogeneity between the populations30: larger
heterogeneity between individuals in a validation study can in
some situations lead to a higher C statistic than in the
development study. For example, variables like age, sex, and
BMI might have larger heterogeneity in our study compared
with the older population of the KORA study.35 Although it
would be of interest to explore whether performance of diabetes
risk scores differs by age or sex, larger studies are warranted
for these subgroup analyses. Another aspect that could influence
model performance is the type of regression analysis used to
derive the prediction model.7 Most studies used logistic
regression rather than survival models7 8 and therefore do not
account for censoring.54 Similar to the results of the Framingham
Offspring Study,42 however, our results showed that the survival
models do not necessarily perform better than the logistic ones.
Quantification of actual risk of future diabetes
All except two prediction models overestimated the absolute
risk of diabetes in our validation dataset, which can partly be
explained by the difference in incidence of diabetes between
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development and validation populations. To account for this,
we adjusted the models for difference in incidence, resulting in
much better calibration. Significant deviations between the
predicted and observed risks, however, remained for most
models. There are various other explanations for the deviation
in predicted versus observed risks. Firstly, in large cohorts the
Hosmer-Lemeshow test is sensitive to small differences between
the predicted and observed risks, so calibration can be indicated
as significantly deviant by statistical tests even when the
calibration plots indicate good calibration based on visual
inspection and for practical purposes.55 So, in large cohorts
significant deviations on the Hosmer-Lemeshow test should be
interpreted cautiously. Secondly, “mis”calibration can be caused
by differences in how certain predictors, the outcome variable,
or baseline characteristics of the study populations are measured,
which can lead to different predictive effects.13 30 For example,
if the two hour oral glucose tolerance test is used to determine
the presence of diabetes in a population, the incidence is likely
to be higher, and among the cases there will be patients with a
less severe form of the disease and different values for the
potential predictors. This is also illustrated by comparing the
effect sizes of the predictors of the German Diabetes Risk Score
in our cohort, which showed significant differences for important
predictors like age. It is important to note, however, that most
prediction models showed overprediction, particularly at higher
absolute risk. Somemodels might not have been well calibrated
in the original populations.7 9 Furthermore, the overestimation
of risk at the higher end could be caused by overestimation of
certain predictors in development populations with high risk
individuals. Although it is important to accurately estimate the
risk for people at high risk, it might not directly influence the
effects of screening and public health strategies: interventions
are often initiated beyond a certain threshold of absolute risk
and overprediction beyond this threshold might therefore not
necessarily lead to different treatment decisions. Certain models
in our study, however, also overestimated the absolute risk in
the lower ranges around 10%. Although decision thresholds for
type 2 diabetes have not been determined, this prediction could
be in the range of a threshold for a clinical decision. To use such
models in clinical practice, calibration needs to be further
improved.
Prior external validation of existing prediction
models
Although the importance of external validation of prediction
models is now widely acknowledged, only a quarter of existing
prediction models have been externally validated, mostly in
studies including only a single model and not reporting any
measures of calibration.7 9 To date, four studies have been
published that performed a comparative external validation of
several different models.10 11 17 56 Two of these studies validated
models for presence of diabetes rather than future risk of
diabetes.11 56 One prospective validation of three extended
models42 44 57 has been performed and showed C statistics ranging
from 0.78 to 0.84 with underestimation or overestimation of the
risk.10 Another prospective validation study showed C statistics
ranging from 0.74 to 0.90, without reporting calibration and
performing adjustments.17 These results are in line with the
discrimination observed in our study. Altogether, the results
from the previous reviews and our study suggest that most of
the basic models performed similarly in terms of discrimination,
whereas the Diabetes Population Risk Tool (DPoRT) showed
slightly lower discrimination. The latter model was primarily
developed to predict risk of diabetes at a population level, which
could explain its slightly worse performance when it is applied
on an individual level.37
Implications for use of prediction models in
practice
Results from our study show that prediction models perform
well to identify those at high risk of future diabetes, being a
first prerequisite for use of such models in practice as currently
recommended.5 6 As expected18 30 and observed in our results,
however, the model should possibly be adapted to the local
setting and purpose of the model and at least corrected for the
incidence of diabetes of the population in which it is to be
applied. The main relevance of prediction models is to correctly
identify individuals at high risk, while avoiding the burden of
treatment for individuals at low risk. This requires adequate
discriminative power in the general population, as well as in
populations characterised by a somewhat higher risk, such as
those with excess weight. In public health practice, one would
perhaps prefer to use a model including only a limited number
of predictors based on non-invasive tests with the highest
performance, which would favour use of a basic model. Noble
et al8 suggested seven models as most promising for use in
clinical or public health practice, of which three were extended
models (ARIC enhanced, Framingham, and San Antonio)42 44 57
and fourwere basicmodels (AUSDRISK,QDScore, FINDRISC,
and Cambridge Risk Score).36 38 43 58 59 According to the current
validation, it seems that this judgment is likely to be correct in
statistical terms. The basic DESIR model that we additionally
evaluated consisted of four predictors,39 while most
models—such as QDScore and AUSDRISK—consist of seven
to 10 predictors. Interestingly, the models including only four
to six predictors35 39 43 performed similarly to the more extensive
models.36 38 We found that discrimination of two other basic
models—KORAbasic35 andDESIR clinical equation39—which
were not included in the list of Noble and colleagues,8
approximated performance of the models incorporating more
predictors. Moreover, the KORA basic model performed
sufficiently to quantify absolute risk after recalibration. This
suggests that a basic model like the KORA, which uses a limited
set of non-invasive predictors, already provides good
discrimination and good calibration and could therefore be useful
in practice after appropriate adaptation of the model to the
setting. The extended models including biomarkers could then
perhaps be used only for those at high risk based on a basic
prediction model. Finally, a model developed in one setting
(such as public health data) or in a particular country does not
necessarily need to be useful in another setting (such as
secondary care) or country. As a next step, the utility of such
models needs to be further investigated in clinical and public
health practice.
Conclusions
Most of the basic prediction models including data on
non-invasive variables performed well to identify those at high
risk of developing type 2 diabetes in an independent population.
The discriminative performance was slightly better for the
extended models with additional data on conventional
biomarkers. Most models, however, overestimated the actual
risk of diabetes. Whether this influences treatment decisions
needs to be further investigated. Hence, existing prediction
models, even with only limited information, are valid tools to
identify those at high risk but do not perform well enough to
quantify the actual risk of future diabetes.
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What is already known on this topic
There are many prediction models to estimate risk for future development of type 2 diabetes
An independent study to validate and compare the existing models is essential for assessing utility of prediction in practice, but has not
yet been performed
What this study adds
Existing prediction models, even those that incorporate only four to six predictors, are valid tools to identify individuals at high risk for
future development of type 2 diabetes
Actual risk for development of type 2 diabetes is generally overestimated, making it necessary to adapt models to local settings, and
even then the accuracy of the estimated risk remains questionable
The impact of such prediction models on prevention or treatment decisions requires further investigation in clinical practice
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NR=not reported. DETECT-2=Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance, KORA=Cooperative Health Research in Region of
Augsburg; BRHS=British Regional Heart Study; AUDSRISK=Australian Type 2 Diabetes Risk Assessment Tool; DPoRT=Diabetes Population Risk Tool;
ARIC=Atherosclerosis Risk in Communities; QDScore=diabetes risk algorithm; DESIR=Data from Epidemiological Study on Insulin Resistance Syndrome;
EPIC=European Prospective Investigation Into Cancer and Nutrition; GDRS=German Diabetes Risk Score; FINDRISC=Finnish diabetes risk score;
PROCAM=Prospective Cardiovascular Münster Study.
*Criteria for plasma glucose concentrations were as fasting glucose (7.0 mmol/L (126 mg/dL) and non-fasting or two hour glucose ≥11.1 mmol/L (200 mg/dL).
†Hosmer-Lemeshow χ2.
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O/E=observed to expected. DETECT-2=Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance; KORA=Cooperative Health Research in Region
of Augsburg; BRHS=British Regional Heart Study; AUDSRISK=Australian Type 2 Diabetes Risk Assessment Tool; DPoRT=Diabetes Population Risk Tool;
ARIC=Atherosclerosis Risk in Communities; QDScore=diabetes risk algorithm; DESIR=Data from Epidemiological Study on Insulin Resistance Syndrome;
EPIC=European Prospective Investigation Into Cancer and Nutrition; GDRS=German Diabetes Risk Score, FINDRISC Finnish diabetes risk score.
*All P<0.001.
†After recalibration.
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Table 3| Discrimination and calibration of 13 extended models for prediction of risk of incident type 2 diabetes in validation cohort*
Recalibrated
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O/E=observed to expected; BRHS=British Regional Heart Study; KORA=Cooperative Health Research in Region of Augsburg; ARIC=Atherosclerosis Risk in
Communities; DESIR=Data from Epidemiological Study on Insulin Resistance Syndrome; PROCAM=Prospective Cardiovascular Münster Study.
*Extrapolation approach applied for case cohort design.
†All P<0.001.
‡After recalibration.
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Table 4| Performance of 12 basic models for prediction of risk of incident type 2 diabetes in sensitivity analyses
C statistic (95% CI) for
original prediction
horizon
C statistic (95% CI) at 7.5 years
Risk prediction model Verified diabetes statusRandom glucose <11.1 mmol/L
Case cohort design in
extrapolated dataset*
—0.83 (0.81 to 0.84)0.82 (0.81 to 0.84)0.82 (0.81 to 0.84)DETECT-2, 2011
—0.83 (0.81 to 0.84)0.82 (0.81 to 0.84)0.82 (0.81 to 0.84)KORA, 2010, basic
0.79 (0.78 to 0.81)†0.79 (0.78 to 0.81)0.79 (0.77 to 0.80)0.79 (0.77 to 0.80)BRHS, 2011, simple clinical
—0.83 (0.82 to 0.85)0.83 (0.81 to 0.84)0.84 (0.82 to 0.85)AUSDRISK, 2010
0.74 (0.73 to 0.75)‡0.74 (0.72 to 0.76)0.74 (0.72 to 0.75)0.74 (0.72 to 0.75)DPoRT, 2010
0.82 (0.81 to 0.84)§0.83 (0.82 to 0.84)0.83 (0.81 to 0.84)0.82 (0.81 to 0.84)ARIC, 2009, basic
—0.76 (0.74 to 0.78)0.76 (0.74 to 0.79)0.76 (0.74 to 0.78)QDScore, 2009
0.81 (0.79 to 0.82)‡0.81 (0.80 to 0.83)0.81 (0.79 to 0.82)0.80 (0.79 to 0.82)DESIR, 2008, clinical
—0.81 (0.80 to 0.83)0.81 (0.79 to 0.82)0.81 (0.79 to 0.82)EPIC-Norfolk, 2007
—0.84 (0.82 to 0.85)0.83 (0.82 to 0.85)0.83 (0.82 to 0.85)EPIC-Potsdam, 2007, GDRS
FINDRISC, 2003:
—0.82 (0.80 to 0.83)0.81 (0.80 to 0.83)0.81 (0.80 to 0.83)Concise
—0.82 (0.80 to 0.83)0.81 (0.80 to 0.83)0.81 (0.79 to 0.82)Full
DETECT-2=Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance, KORA=Cooperative Health Research in Region of Augsburg; BRHS=British
Regional Heart Study; AUDSRISK=Australian Type 2 Diabetes Risk Assessment Tool; DPoRT=Diabetes Population Risk Tool; ARIC=Atherosclerosis Risk in
Communities; QDScore=diabetes risk algorithm; DESIR=Data from Epidemiological Study on Insulin Resistance Syndrome; EPIC=European Prospective
Investigation Into Cancer and Nutrition; GDRS=German Diabetes Risk Score; FINDRISC=Finnish diabetes risk score.
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Table 5| Performance of 13 extended models for prediction of risk of incident type 2 diabetes in sensitivity analyses*
C statistic (95% CI) for
original prediction horizon
C statistic (95% CI) at 7.5 years
Risk prediction model Fasting for >2 hoursMORGEN datasetRandomglucose <11.1mmol/L
BRHS, 2011:
0.86 (0.84 to 0.87)†0.86 (0.84 to 0.88)0.89 (0.87 to 0.91)0.86 (0.84 to 0.88)Fasting bio
0.81 (0.80 to 0.83)†0.80 (0.79 to 0.82)0.84 (0.82 to 0.86)0.81 (0.80 to 0.83)Non-fasting bio
—0.93 (0.92 to 0.94)0.92 (0.90 to 0.93)0.93 (0.92 to 0.94)KORA, 2010, clinical
0.81 (0.80 to 0.82)‡0.81 (0.79 to 0.83)0.84 (0.83 to 0.86)0.81 (0.80 to 0.83)Tromsø, 2010
0.88 (0.87 to 0.89)§0.90 (0.88 to 0.91)0.91 (0.89 to 0.92)0.88 (0.87 to 0.89)ARIC, 2009 enhanced
0.88 (0.87 to 0.89)¶0.90 (0.88 to 0.91)0.89 (0.87 to 0.91)0.87 (0.86 to 0.88)DESIR, 2008, clinical+bio
Framingham, 2007:
0.81 (0.80 to 0.83)†0.82 (0.80 to 0.84)0.79 (0.77 to 0.81)0.82 (0.80 to 0.83)Model 1
0.81 (0.80 to 0.83)†0.82 (0.80 to 0.84)0.79 (0.76 to 0.81)0.82 (0.80 to 0.83)Model 2
0.82 (0.81 to 0.83)†0.82 (0.80 to 0.84)0.80 (0.77 to 0.82)0.82 (0.81 to 0.84)Model 3
0.88 (0.87 to 0.89)†0.90 (0.88 to 0.91)0.89 (0.87 to 0.91)0.87 (0.86 to 0.88)Continuous
—0.92 (0.91 to 0.93)0.91 (0.87 to 0.92)0.90 (0.89 to 0.91)San Antonio, 2002
0.84 (0.83 to 0.85)**0.83 (0.81 to 0.85)0.87 (0.85 to 0.88)0.84 (0.82 to 0.85)PROCAM, 2000
0.89 (0.87 to 0.90)††0.91 (0.90 to 0.92)0.89 (0.86 to 0.91)0.88 (0.87 to 0.90)San Antonio, 1993
BRHS=British Regional Heart Study; KORA=Cooperative Health Research in Region of Augsburg; ARIC=Atherosclerosis Risk in Communities; DESIR=Data from
Epidemiological Study on Insulin Resistance Syndrome; PROCAM=Prospective Cardiovascular Münster Study.
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Figures
Fig 1 Overview of systematic literature search of studies that derived prediction models for risk of type 2 diabetes
Fig 2 Calibration plots for recalibrated basic models risk of diabetes at 7.5 years depicting predicted risk against observed
risk of developing type 2 diabetes in validation dataset. Dashed line (45° line) from zero denotes ideal calibration line
(slope=1, intercept=0) and other lines are smooth calibration curve for each model
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e5900 doi: 10.1136/bmj.e5900 (Published 18 September 2012) Page 15 of 16
RESEARCH
Fig 3Calibration plots for recalibrated extended models risk of diabetes at 7.5 years depicting predicted risk against observed
risk of developing type 2 diabetes in validation dataset. Dashed line (45° line) from zero denotes ideal calibration line
(slope=1, intercept=0) and other lines are smooth calibration curve for each model
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